153.95 <%= Resources.Global.txtUp %>
Updated 15/07/2019
Change % 1.15% Stock price increasing
Change 1.75 Stock price increasing
Volume 746,735
High 154.55
Low 150.70
Open 151.80
ISIN BE0003818359
Prev close 152.20
# of shares 54.82M
Market cap 8,440.02M EUR

Market closed
Market is closed, opens at 08:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  153.95 26.3% Stock price increasing 42.8% Stock price increasing 51.4% Stock price increasing 65.6% Stock price increasing 75.3% Stock price increasing
Powered by TradingView

News about Galapagos

  • English
  • Regulatory news

Company profile

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
17 July 2019 06:13:32
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190703.1 - EUROWEB2 - 2019-07-17 07:13:32 - 2019-07-17 06:13:32 - 1000 - Website: OKAY